Camrelizumab, manufactured by Jiangsu Hengrui Pharmaceuticals Co., Ltd., China, is an anti-PD-1 monoclonal antibody that has been demonstrated to be superior to chemotherapy for recurrent advanced esophageal squamous cell carcinoma patients regardless of PD-L1 expression. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.